AIRS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AirSculpt Technologies, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$4.96 |
| 52주 최고가 | US$12.00 |
| 52주 최저가 | US$1.51 |
| 베타 | 2.37 |
| 1개월 변동 | 9.73% |
| 3개월 변동 | 38.94% |
| 1년 변동 | -17.61% |
| 3년 변동 | -41.65% |
| 5년 변동 | n/a |
| IPO 이후 변동 | -68.79% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 22
AIRS: Higher Fair Value And 2026 Guidance Will Support Bullish Repricing
Analysts have raised their fair value estimate for AirSculpt Technologies to $6.25 from $4.50, reflecting updated views on its long term P/E assumption and profitability metrics, while keeping revenue growth and discount rate expectations broadly consistent. What’s in the News for AirSculpt Technologies AirSculpt Technologies affirmed earnings guidance for the full year 2026, indicating an expected revenue range of approximately $151 million to $157 million.
새로운 내러티브 • Jul 21
Long-Term GLP-1 Tailwinds And New Procedures Will Transform Future Earnings Potential
Catalysts About AirSculpt Technologies AirSculpt Technologies operates centers that provide minimally invasive body contouring, skin tightening and related aesthetic procedures. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jun 26
AIRS: Raised Price View And 2026 Outlook Will Shape Fair Risk Balance
Analysts have raised their price target on AirSculpt Technologies stock from $3.00 to $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What’s in the News for AirSculpt Technologies AirSculpt Technologies affirmed revenue guidance for the full year 2026, with expectations of approximately US$151 million to US$157 million.Recent updates
내러티브 업데이트 • Jul 22
AIRS: Higher Fair Value And 2026 Guidance Will Support Bullish Repricing
Analysts have raised their fair value estimate for AirSculpt Technologies to $6.25 from $4.50, reflecting updated views on its long term P/E assumption and profitability metrics, while keeping revenue growth and discount rate expectations broadly consistent. What’s in the News for AirSculpt Technologies AirSculpt Technologies affirmed earnings guidance for the full year 2026, indicating an expected revenue range of approximately $151 million to $157 million.새로운 내러티브 • Jul 21
Long-Term GLP-1 Tailwinds And New Procedures Will Transform Future Earnings Potential
Catalysts About AirSculpt Technologies AirSculpt Technologies operates centers that provide minimally invasive body contouring, skin tightening and related aesthetic procedures. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jun 26
AIRS: Raised Price View And 2026 Outlook Will Shape Fair Risk Balance
Analysts have raised their price target on AirSculpt Technologies stock from $3.00 to $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What’s in the News for AirSculpt Technologies AirSculpt Technologies affirmed revenue guidance for the full year 2026, with expectations of approximately US$151 million to US$157 million.분석 기사 • Jan 06
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Share Price Is Still Matching Investor Opinion Despite 35% Slump
Unfortunately for some shareholders, the AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) share price has dived 35% in the...Seeking Alpha • Oct 29
AirSculpt Technologies: Upgrading To Buy On Improving Fundamentals
Summary Upgrade AirSculpt Technologies (AIRS) to 'Buy' as strong technical momentum and record lead generation drive optimism for further upside. AIRS delivered positive sequential growth in Q2, with improved gross margins, reduced SG&A expenses, and lower customer acquisition costs supporting profitability. Debt reduction and the highest operating cash flow in eight quarters position AIRS closer to sustained profitability, despite macro risks and elevated valuation. Q3 earnings are critical; AIRS must meet or exceed $39.8 million in revenue to maintain momentum and justify its premium sales multiple. Read the full article on Seeking Alpha분석 기사 • Oct 05
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Shares Climb 32% But Its Business Is Yet to Catch Up
Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...분석 기사 • Sep 24
Estimating The Intrinsic Value Of AirSculpt Technologies, Inc. (NASDAQ:AIRS)
Key Insights AirSculpt Technologies' estimated fair value is US$7.56 based on 2 Stage Free Cash Flow to Equity...분석 기사 • Aug 29
Here's Why AirSculpt Technologies (NASDAQ:AIRS) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jul 25
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) 28% Share Price Surge Not Quite Adding Up
Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...분석 기사 • Jun 10
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Shares Climb 69% But Its Business Is Yet to Catch Up
The AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) share price has done very well over the last month, posting an...분석 기사 • Apr 25
Some Confidence Is Lacking In AirSculpt Technologies, Inc. (NASDAQ:AIRS) As Shares Slide 31%
To the annoyance of some shareholders, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares are down a considerable 31...분석 기사 • Feb 25
AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) Share Price Matching Investor Opinion
It's not a stretch to say that AirSculpt Technologies, Inc.'s ( NASDAQ:AIRS ) price-to-sales (or "P/S") ratio of 1.4x...분석 기사 • Jan 28
Investors Could Be Concerned With AirSculpt Technologies' (NASDAQ:AIRS) Returns On Capital
Ignoring the stock price of a company, what are the underlying trends that tell us a business is past the growth phase...분석 기사 • Dec 04
An Intrinsic Calculation For AirSculpt Technologies, Inc. (NASDAQ:AIRS) Suggests It's 40% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, AirSculpt Technologies fair value estimate is US$12.46 Current...분석 기사 • Nov 14
Why Investors Shouldn't Be Surprised By AirSculpt Technologies, Inc.'s (NASDAQ:AIRS) 30% Share Price Surge
Despite an already strong run, AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares have been powering on, with a gain...분석 기사 • Nov 07
Is AirSculpt Technologies (NASDAQ:AIRS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Oct 20
The Return Trends At AirSculpt Technologies (NASDAQ:AIRS) Look Promising
There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...분석 기사 • Sep 28
Optimistic Investors Push AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares Up 29% But Growth Is Lacking
AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shareholders have had their patience rewarded with a 29% share price jump...분석 기사 • Sep 25
Is It Time To Consider Buying AirSculpt Technologies, Inc. (NASDAQ:AIRS)?
AirSculpt Technologies, Inc. ( NASDAQ:AIRS ), might not be a large cap stock, but it saw a significant share price rise...분석 기사 • Aug 01
The Market Lifts AirSculpt Technologies, Inc. (NASDAQ:AIRS) Shares 26% But It Can Do More
Those holding AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares would be relieved that the share price has rebounded...분석 기사 • Apr 04
There's Been No Shortage Of Growth Recently For AirSculpt Technologies' (NASDAQ:AIRS) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term...분석 기사 • Feb 23
Here's Why AirSculpt Technologies (NASDAQ:AIRS) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Dec 14
AirSculpt Technologies, Inc. (NASDAQ:AIRS) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shareholders are no doubt pleased to see that the share price has bounced...분석 기사 • Nov 12
US$8.19: That's What Analysts Think AirSculpt Technologies, Inc. (NASDAQ:AIRS) Is Worth After Its Latest Results
There's been a notable change in appetite for AirSculpt Technologies, Inc. ( NASDAQ:AIRS ) shares in the week since its...분석 기사 • Sep 20
Be Wary Of AirSculpt Technologies (NASDAQ:AIRS) And Its Returns On Capital
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...분석 기사 • Oct 29
Capital Allocation Trends At AirSculpt Technologies (NASDAQ:AIRS) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Seeking Alpha • Aug 27
AirSculpt Technologies: Niche Offering Offset By Profitability, Valuation
Summary AirSculpt Technologies presents with a unique offering with exposure to alternative medical sectors in cosmetics. The company's growth strategy is well received but comes with notable execution risks. Shares appear to be reasonably valued at current levels, however, deeper examination of financials places questions on just what we are buying. With these points in mind, we value AIRS a hold. Investment summary AirSculpt Technologies, Inc. (AIRS) has piqued our interest since listing back in FY21. It operates in a novel segment of 'body contouring procedures' and is best known for its AirSculpt procedure, under the subsidiary brand Elite Body Sculpture. The proprietary procedure is touted due to its minimally invasive nature that contrasts to traditional liposuction. Its growth strategy is to open new centres and expand/relocate existing ones, ultimately driving up revenue per case, cases per room and overall case numbers as part of its growth strategy. Exhibit 1. AIRS 6-month price action Data: Refinitiv Eikon Despite the allure, forensics over its financial statements reveal there to be a loose fit to the kind of equity premia we are seeking exposure to in H2 FY22. Valuations are supportive of a neutral view and regulatory headwinds in adjacent markets [Australia, to be specific] has us cautious on the ramifications for global peers. With these points in mind, we rate AIRS a hold. Q2 earnings indicate growth trends We see the differentiated strengths of AIRS' procedures in its most recent earnings, with upsides to consensus at the top and bottom lines. Forecasts on the global cosmetic market growth published in April 2022 predict a geometric growth of 3.6% per year from 2021 until 2028. Contrary evidence suggests a 9.6% CAGR into 2030. AIRS printed revenue of $49.7 million for the period, up 42% YoY. Presuming either of the above forecasts are true, then AIRS above top-line growth suggest it gained additional market share during the quarter. As a side note, however, this is a murky segment - recent controversies in the Australian cosmetic surgery market surrounding regulation are a potential risk for global participants. Cases also increased 22.5% YoY to 3,691 total cases, as seen in Exhibit 2. The company records each case as 1 visit, with doesn't factor in that each patient may have multiple treatment areas per visit. Nevertheless, it opened 4 new centres during Q2 FY21, bringing total centres to 19. Meanwhile, revenue per case increased 16% YoY to ~$13,450, supported by the company's access to 38 procedure rooms versus 25 the year prior. However, the 10-Q did note that cases per procedure room declined due to the addition of the 13 new centres and expansion of existing ones, versus an organic decline over the 12 months. There is good reason to estimate that trends will normalize as procedures per room level to overall company growth trends. Exhibit 2. Above-market growth statistics imply the company might be gaining additional market share Image: HB Insights, AIRS SEC Filings Despite the upsides in booked revenues for the quarter, our findings indicate there are drains and pulls on liquidity that may place stress on AIRS' current position. As seen below, we estimate there to be around 3-4 quarters of cash runway remaining with the company's most recent earnings. It needs a substantial growth in cash conversion from net income to bolster its position here and prevent additional dilutive equity raise(s) and/or expensive debt issuance/origination in the high yield debt capital markets. Noteworthy to this point, however, is the company declared a $0.41/share special dividend to be paid in September. Exhibit 3. Data: HB Insights Estimates The company also reports non-GAAP EBITDA and recorded a $1.01 million YoY increase to $15.2 million as seen in Exhibit 4. This is despite earnings narrowing by 94% YoY from ~$10 million to $583,000. According to the 10-Q, "management assesses and believes investors should assess our operating performance" [using non-GAAP EBITDA]. We take some issue with this recommendation. Firstly, the company booked ~$7.3 million in stock-based compensation ("SBC") for the period, and saw an interest expense of $1.5 million - each up substantially on the year. Moreover, as seen below, AIRS asks us to ignore the impact of new centre opening and relocation costs, plus the SBC, plus the loss on asset disposals. We argue these are expenses that must be realized in the analysis of free cash flow and valuation. We can't simply ignore that these 3 expenses in particular total to $9.3 million, and removing them from the equation, non-GAAP EBITDA is ~$5.9 million. Not to mention, it also recorded a $60 million payment to its parent organization. Therefore, whilst it converted $8.5 million in quarterly cash flow, this was more than offset by these expenditures. Exhibit 4. Non-GAAP EBITDA includes several expenditures that we argue should be included in cash flow analysis Data: AIRS 10-Q, Q2 FY2022 Valuation AIRS' growth strategy involves opening de novo centres, expanding existing ones and acquiring additional assets into its portfolio. In that regard, AIRS' corporate value stems from its popular set of procedures - particularly AirSculpt liposuction - as an intangible plus its tangible book value. Any value manager will also familiarize this information with cash flow multiples and forecasts.주주 수익률
| AIRS | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | 6.4% | -3.0% | 2.4% |
| 1Y | -17.6% | 43.5% | 19.6% |
수익률 대 산업: AIRS은 지난 1년 동안 43.5%의 수익을 기록한 US Healthcare 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: AIRS은 지난 1년 동안 19.6%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| AIRS volatility | |
|---|---|
| AIRS Average Weekly Movement | 10.4% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: AIRS는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: AIRS의 주간 변동성은 지난 1년간 17%에서 10%로 감소했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2012 | 347 | Yogi Jashnani | www.airsculpt.com |
는 자회사와 함께 미국과 캐나다에서 바디 컨투어링 시술 서비스를 제공하는 EBS Intermediate Parent LLC의 지주회사로서 운영에 주력하고 있습니다. 이 회사는 최소 침습적 시술로 신체의 특정 부위를 조각하면서 지방을 제거하고 피부를 조여주는 바디 컨투어링 시술인 에어스컬프(AirSculpt)를 제공합니다. 또한 탁월한 정밀도와 정교함으로 지방을 영구적으로 제거하고 피부를 조여주는 시술인 에어스컬프트+와 고급 셀룰라이트 제거 도구인 에어스컬프트 스무스를 제공합니다.
AirSculpt Technologies, Inc. 기초 지표 요약
| AIRS 기초 통계 | |
|---|---|
| 시가총액 | US$344.26m |
| 순이익 (TTM) | -US$11.22m |
| 매출 (TTM) | US$151.84m |
2.3x
주가매출비율(P/S)-31.2x
주가수익비율(P/E)AIRS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| AIRS 손익계산서 (TTM) | |
|---|---|
| 매출 | US$151.84m |
| 매출원가 | US$51.53m |
| 총이익 | US$100.31m |
| 기타 비용 | US$111.53m |
| 순이익 | -US$11.22m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 10, 2026
| 주당순이익(EPS) | -0.16 |
| 총이익률 | 66.06% |
| 순이익률 | -7.39% |
| 부채/자본 비율 | 44.7% |
AIRS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/04 00:41 |
| 종가 | 2026/08/04 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AirSculpt Technologies, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Sam Eiber | BTIG |
| Michael Gorman | BTIG |
| Benjamin Mayo | Leerink Partners LLC |